Form 4 Filing for Niki BioSolutions, Inc.

Kira Sheinerman, a 10% owner, director, and insider of Niki BioSolutions, Inc. (NIKI), reported the acquisition of 8,000 stock options on July 22, 2026. These options, with an exercise price of $8.83, are set to expire on July 22, 2036. The acquisition was reported on a Form 4 filing. The options vest over time, with 2,000 options vesting immediately upon the closing of a merger and the remaining 6,000 vesting in three equal quarterly installments thereafter. The underlying security for these options is the Common Stock of Niki BioSolutions, Inc.